Financial Performance - Revenue for the six months ended June 30, 2023, was RMB 2,247,282 thousand, representing a 12.9% increase from RMB 1,989,776 thousand in the same period of 2022[2] - Adjusted net loss attributable to owners for the period was RMB 117,351 thousand, a significant reduction of 80.0% compared to RMB 585,909 thousand in the prior year[2] - Gross profit for the six months ended June 30, 2023, was RMB 682,913 thousand, with a gross margin of 30.4%, compared to RMB 664,672 thousand and a margin of 33.4% in the same period of 2022[2] - The company reported a basic and diluted loss per share of RMB 0.08 for the six months ended June 30, 2023, compared to RMB 0.92 in the same period of 2022[2] - The adjusted net loss margin improved to 5.2% for the six months ended June 30, 2023, from 29.3% in the same period of 2022, indicating better operational efficiency[2] - The net profit attributable to the owners of the company for the six months ended June 30, 2023, was a loss of RMB 112,574 thousand, compared to a loss of RMB 578,065 thousand for the same period in 2022[16] - Net loss narrowed by approximately 80% to RMB 117 million, down from a loss of RMB 469 million in the previous year[22] Revenue Breakdown - Revenue from pharmaceutical and healthcare business reached RMB 2,184,609 thousand, up from RMB 1,926,245 thousand, reflecting a growth of 13.4% year-over-year[11] - Total customer contract revenue for the six months ended June 30, 2023, was RMB 2,247,282 thousand, an increase of 12.9% from RMB 1,989,776 thousand for the same period in 2022[11] - Fast drug business revenue amounted to RMB 2,184.6 million, reflecting a 13.4% growth from RMB 1,926.2 million in the previous year[22] - The company's fast drug business reported revenue of RMB 1,606.0 million for the six months ending June 30, 2023, representing a year-on-year increase of 14.8% compared to RMB 1,398.7 million for the same period in 2022[24] - The distribution business achieved revenue of RMB 246.0 million, a 33.8% increase from RMB 183.8 million in the same period last year, driven by an increase in product development and sales partnerships[26] - The online direct sales channel recorded revenue of RMB 1,606.0 million, up 14.8% from RMB 1,398.7 million year-on-year, with registered users reaching 39.2 million[25] - Offline retail revenue was RMB 332.6 million, a slight decrease of 3.2% from RMB 343.7 million in the same period last year[27] - Other business revenue was RMB 62.7 million, showing a minor decrease of 1.4% from RMB 63.5 million year-on-year[28] Expenses and Cost Management - The cost of goods sold for the six months ended June 30, 2023, was RMB 1,550,168 thousand, compared to RMB 1,324,903 thousand for the same period in 2022, representing an increase of 17.0%[12] - Total employee benefit expenses decreased to RMB 261,723 thousand from RMB 379,695 thousand, a reduction of 30.9% year-over-year[12] - Fulfillment expenses increased by 0.8% to RMB 212.4 million, with the percentage of revenue decreasing from 10.6% to 9.5%[37] - Sales and marketing expenses rose by 10.8% to RMB 465.2 million, with the percentage of revenue decreasing from 21.1% to 20.7%[38] - R&D expenses decreased by 33.6% to RMB 30.7 million, with the percentage of revenue dropping from 2.3% to 1.4%[39] - General and administrative expenses decreased by 38.1% to RMB 127.8 million, with the percentage of revenue falling from 10.4% to 5.7%[40] Assets and Liabilities - Total assets as of June 30, 2023, were RMB 3,237,000 thousand, down from RMB 3,297,475 thousand as of December 31, 2022[3] - Total liabilities increased slightly to RMB 1,107,598 thousand from RMB 1,098,279 thousand, reflecting ongoing operational commitments[4] - Trade receivables as of June 30, 2023, totaled RMB 115,276 thousand, an increase from RMB 105,562 thousand as of December 31, 2022[19] - Trade payables increased to RMB 441,726 thousand as of June 30, 2023, compared to RMB 345,904 thousand as of December 31, 2022[20] Cash Flow and Investments - Cash and cash equivalents, including restricted bank deposits, totaled RMB 1,485,597 thousand as of June 30, 2023, compared to RMB 1,331,549 thousand at the end of 2022[3] - Net cash generated from operating activities for the six months ended June 30, 2023, was RMB 210.1 million, significantly up from RMB 22.5 million in the same period last year[49] - Investment activities resulted in a net cash inflow of RMB 95.8 million, primarily due to the redemption of financial assets at fair value through profit or loss[50] - Capital expenditures for the six months ended June 30, 2023, were RMB 7.8 million, down from RMB 17.5 million in the same period of 2022[50] Corporate Strategy and Development - The company continues to focus on expanding its pharmaceutical and healthcare services within China, leveraging its operational base in Beijing[5] - The company plans to enhance its "medical, testing, drug, insurance" ecosystem and focus on core cities for health services expansion[23] - The company aims to leverage technology and policy trends to meet the growing demand for health and pharmaceutical services[22] - The company is focusing on chronic disease management, partnering with Sanofi to provide 24/7 delivery of diabetes medications, with an average delivery time of 28 minutes[30] - The company aims to strengthen its service capabilities in major cities like Beijing, Shanghai, and Shenzhen while expanding its operational scale and service density[33] - The company has established partnerships with over 5,000 pharmaceutical companies to enhance product diversity and improve user access to affordable and quality services[24] Governance and Compliance - The company has committed to high standards of corporate governance, adhering to the corporate governance code as per the Hong Kong Stock Exchange[55] - The company has established an audit committee composed of three independent non-executive directors to oversee financial reporting and risk management[61] - The audit committee has reviewed the unaudited condensed consolidated financial statements for the six months ended June 30, 2023[62] - The financial statements were reviewed by Deloitte according to the International Accounting Standards Board's International Standard on Review Engagements 2410[62] Shareholder Information - The company did not recommend the distribution of an interim dividend for the six months ended June 30, 2023[59] - The company has adopted a share incentive plan involving a total of 87,993,330 shares, representing about 6.56% of the total issued share capital as of June 30, 2023[53] - The newly adopted 2023 Restricted Share Unit Plan allows for up to 26,829,457 shares, accounting for approximately 2.0% of the total issued share capital as of June 30, 2023[53] - The company raised approximately HKD 341.6 million from its global offering, issuing 33,537,000 shares at a price of HKD 12.00 per share[54] - As of June 30, 2023, 45% of the net proceeds (approximately HKD 153.7 million) is allocated for business expansion, including the development of smart pharmacies and enhancing user growth and engagement[54] - 15% of the net proceeds (approximately HKD 51.2 million) is designated for optimizing technology systems and operational platforms[54] - The company plans to utilize 20% of the net proceeds (approximately HKD 68.3 million) for potential investments, acquisitions, or strategic partnerships in the healthcare industry value chain[54] - As of June 30, 2023, the total utilized amount from the net proceeds is HKD 232.4 million, leaving HKD 109.2 million unutilized[54]
叮当健康(09886) - 2023 - 中期业绩